Atai Life Sciences BV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company, which engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao. Rao, who currently serves as the biopharmaceutical firm's chief scientific officer, will become co-chief executive in June, before fully taking over by the year-end.

atai Life Sciences boss makes way for co-founder on better first quarter

NEW YORK and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced first quarter 2024 financial results, provided corporate updates and announced a transition in its leadership.

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its Phase 2a study of its novel intranasal 5-MeO-MDT drug candidate BPL-003 in treatment-resistant depression. Initial results from the first part of the study unveiled in March showed that a single dose of BPL-003 was safe and well-tolerated and had a “rapid and durable” antidepressant effect which lasted up to 12 weeks.

atai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression study

NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in Part 2 of Beckley Psytech's Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with Treatment Resistant Depression (TRD).

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the results of investee Beckley Beckley Psytech's Phase 1 study of its novel, novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, BPL-003, have been published in The Journal of Psychopharmacology. The study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of BPL-003 in combination with psychological support in 44 healthy volunteers who were split into seven cohorts and given a single dose of BPL-003 ranging from 1 mg to 12 mg or a placebo.

atai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT asset

NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech's novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus on psychedelic-based treatments for depression.   CEO and co-founder Florian Brand joined Proactive to discuss the company's recent milestones including encouraging clinical trial results, what to expect from its ongoing research programs and upcoming catalysts for both the company and the broader psychedelics sector.

atai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalysts

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its operations into 2026 as it continues to advance psychedelic-based therapies targeting several mental health conditions. Recent clinical highlights included positive results from Beckley Psytech's Phase 2a study of BPL-003, an intranasal formulation of 5-MeO-DMT, in patients with treatment-resistant depression.

atai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapies

NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has hailed positive results from its investee Beckley Psytech's Phase 2a study of its novel DMT formulation BPL-003 in patients with treatment-resistant depression. The biopharmaceutical company said during the open-label study, a single 10mg dose of BPL-003 – a novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT (mebufotenin) – was administered intranasally along with psychological support and induced a rapid antidepressant response in 55% of patients the day after dosing.

atai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression study

- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect  in TRD patients, with 45% of patients in clinical remission at week 12

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first healthy participant in a Phase 1b trial evaluating its oral transmucosal film formulation of DMT VLS-01, which is being developed by the company for patients with treatment-resistant depression. The company said that the study was designed to evaluate the relative safety, tolerability, pharmacokinetics and pharmacodynamics of VLS-01 when compared to intravenous (IV) DMT.

atai Life Sciences doses first patient in Phase 1b study of its optimized oral DMT formulation

NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first healthy participant has been dosed in the Phase 1b trial of VLS-01, an oral transmucosal film (OTF) formulation of N,N-dimethyltryptamine (DMT).

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024.

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO).

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

COMPASS Pathways

Seelos Therapeutics

Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine as a depression therapeutic.

Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution

Psychedelics stocks could be buoyed by a few positive events soon. The government is now funding the study of certain psychedelics.

3 Big New Catalysts for Psychedelics Stocks in 2024

Psychedelic drug development firm atai Life Sciences (NASDAQ:ATAI) is investing $50 million in UK-based Beckley Psytech as part of a collaboration that gives the company exposure to a Phase 2 psychedelic drug candidate.  The investment will give the Berlin-headquartered company a 35.5% stake.

atai Life Sciences expands its pipeline with $50M investment in Beckley Psytech

Psychedelic drug development firm atai Life Sciences (NASDAQ:ATAI) is investing $50 million in UK-based Beckley Psytech as part of a collaboration that give the company exposure to a Phase 2 psychedelic drug candidate.  Beckley's two main clinical programs are an intrnasal treatment for treatment-resistant depression (TRD) and alcohol use disorder (AUD), as well as an intravenous psilocin treatment for major depressive disorder (MDD).

Psychedelic firm atai Life Sciences expands its pipeline with $50M investment in Beckley Psytech

NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

atai Life Sciences (NASDAQ:ATAI) shares moved more than 13% higher Tuesday after the company reported positive findings from its early-stage study of EMP-01, Atai's R-isomer of MDMA. The company said that EMP-01 was well-tolerated and treatment-related adverse events were expected and largely dose-related in healthy volunteers.

Atai Life Sciences reports positive data from early-stage R-MDMA study

Ameri Holdings

Incannex Healthcare Inc

NRX Pharmaceuticals

SAGE Therapeutics

Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giving patients new hope for recovery and the ability to thrive.

5 Biotech stocks tapping into unmet mental health treatment needs

ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various clinical trial phases, showing promising results. ATAI's stake in COMPASS exposes it to the promising COMP360 IP, currently in phase 3 with a delineated pathway to a potential FDA approval.

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value

atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for Atai Life Sciences BV Stock (ATAI)